| Literature DB >> 35204401 |
Leon-Gordian Koepke1, Annika Heuer1, Martin Stangenberg1, Marc Dreimann1, Lutz Welker2, Carsten Bokemeyer3, André Strahl4, Anne Marie Asemissen3, Lennart Viezens1.
Abstract
Patients with new-onset malignant spinal lesions often have an urgent need for local spine intervention and systemic therapy. For optimal management, it is crucial to diagnose the underlying disease as quickly and reliably as possible. The aim of our current study was to determine the feasibility, sensitivity, specificity, and diagnostic certainty of complementary cytological evaluation of spinal lesions suspected of malignancy. In 44 patients, we performed histopathological biopsies and in parallel cytologic preparations from the malignant site. Cytological smears were prepared and stained for May-Grunwald and Giemsa. Bone biopsies were histopathologically analyzed according to the existing standard-of-care practices. In 42 of 44 cases (95%), a cytological sample was successfully obtained. In 40 cases (95.2%, Cohen's kappa: 0.77), the cytological diagnosis agreed with the histological diagnosis regarding the identification of a malignant lesion. This resulted in a sensitivity of 97% and a specificity of 80% as well as a diagnostic safety of 95%. Cytological analysis in the context of spinal surgery proved sufficient to establish a diagnosis of malignancy or its exclusion, expanding the existing diagnostic spectrum. Furthermore, implementation of this process as a routine clinical diagnostic might shorten the time to diagnosis and improve the treatment of this vulnerable patient group.Entities:
Keywords: biopsy; bone marrow; cytological technique; metastases; spinal neoplasms; spine; standard of care
Year: 2022 PMID: 35204401 PMCID: PMC8871040 DOI: 10.3390/diagnostics12020310
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Figure 1Example light microscopy images of cytologic specimens obtained by aspiration from vertebral body lesions suspected of malignancy: (a) Smear from aspiration cytology of bone marrow from a malignant spinal osteolytic lesion of unknown origin. The image shows accumulations of large atypical nonhematologic cells with immature nuclei and basophilic cytoplasm with sparse vacuolization consistent with adenocarcinoma. The patient had a PSA level of 4300 μg/L and final histology revealed prostate carcinoma; 100× magnification. (b) Smear from aspiration cytology from an osteolytic lesion of the spine. The specimen shows subtotal infiltration with mature but atypical plasma cells of polymorphic size, including giant cells corresponding to plasma cell myeloma; 40× magnification.
Number of benign, hematologic malignant, and solid malignant lesions identified by histology and cytology.
| Lesion Type | Histology | Cytology 1 |
|---|---|---|
| Benign | 5 | 5 |
| Hematologic malignant | 11 | 8 |
| Solid malignant | 28 | 29 |
| Total malignant | 39 | 37 |
| Overall total | 44 | 42 1 |
1 In 2 of the 39 cases included in the study, no cytological evaluation could be performed on the samples obtained.
Number of solid malignant lesion subtypes identified in histology 1.
| Malignant Lesion Subtype | Number |
|---|---|
| Breast carcinoma | 8 |
| Prostate carcinoma | 4 |
| Small cell neuroendocrine carcinoma | 3 |
| Hepatocellular carcinoma | 3 |
| Bronchopulmonary adenocarcinoma | 3 |
| Malignant melanoma | 2 |
| Renal cell carcinoma | 1 |
| Biliopancreatic adenocarcinoma | 1 |
| Epithelioid angiosarcoma | 1 |
| Bronchopulmonary squamous cell carcinoma | 1 |
| Adenocarcinoma of unknown origin | 1 |
1 All detected malignant lesions corresponded to a metastasis of an extraspinally localized primary tumor. There were no primary malignant spinal tumors in the investigated population.
Sensitivity, specificity, and diagnostic certainty of cytology from the target vertebra to identify a malignant lesion in relation to the diagnosis of the reference pathology.
| Cytology from the Target Vertebra | |
|---|---|
| Sensitivity | 0.97 |
| Specificity | 0.80 |
| Diagnostic certainty 1 | 0.90 |
1 Diagnostic certainty = sum of correct findings (malignant or benign)/number of subsampled cases.
Number of matches between cytological and histological diagnoses.
| Histology | Cytology | Number of Matches 1 | |
|---|---|---|---|
| Benign | 5 | 5 | 4 |
| Hematologic malignant | 11 | 8 | 8 |
| Solid malignant | 28 | 29 | 28 |
1 Number of matches = cases identified as benign, hematologic malignancy, or solid malignancy by both histology and cytology.